Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Laboratories reported approximately $2 billion in continuous glucose monitor (CGM) sales, reflecting a 12.2% year-over-year organic growth, showcasing strong demand in the diabetes management sector. The company also demonstrated solid financial performance with a 10% year-over-year increase in segment sales for 2025, driven by successful product launches and strategic investments in emerging technologies. Furthermore, Abbott's consistent commitment to dividend payouts, having increased them for over 50 consecutive years, underscores its stable financial health and dedication to returning value to shareholders.

Abbott Laboratories reported weak Q4 organic ex-Covid sales growth of 3.8% year-over-year, indicating a significant deceleration in growth sequentially when measured on a stacked two-year basis, particularly impacting its Nutrition and Diagnostics divisions. The company faced headwinds from a decline in Covid-19 testing sales, lower-than-expected revenue across various segments, and macroeconomic pressures including inflation and foreign exchange fluctuations, further contributing to its negative outlook. Additionally, Abbott's earnings per share guidance for Q4'25 was slightly below consensus expectations, reflecting underperformance in nearly all revenue segments and resulting in an 8% intraday decline in stock price following the earnings announcement.